Oral Hypoglycemic Agents: Metformin, SGLT2i, GLP-1 RA & Sulfonylureas

**1. Metformin (Biguanides - First-Line Pharmacotherapy)** * **Mechanism of Action**: Activates **AMP-Activated Protein Kinase (AMPK)** in hepatocytes. Inhibits hepatic gluconeogenesis and glycogenolysis, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity in skeletal muscle without stimulating pancreatic beta cells (does not cause hypoglycemia). * **Cardiorenal Benefits**: Weight-neutral or mild weight loss; reduces cardiovascular morbidity. * **Adverse Effects**: Gastrointestinal upset (diarrhea, abdominal cramps in 20%), Vitamin B12 deficiency (impaired ileal absorption). * **Black Box Warning**: **Lactic Acidosis** due to inhibition of mitochondrial complex I and gluconeogenic lactate clearance. Contraindicated if eGFR <30 mL/min/1.73m² or in severe hypoxic states. **2. Sulfonylureas (Insulin Secretagogues: Glimepiride, Gliclazide, Glipizide)** * **Mechanism**: Binds to the **SUR1** regulatory subunit of ATP-sensitive potassium (\( \text{K}_{\text{ATP}} \)) channels in pancreatic beta-cell membranes. Closes the channel, depolarizing the membrane, opening voltage-gated \( \text{Ca}^{2+} \) channels, and driving exocytosis of preformed insulin granules. * **Adverse Effects**: Prolonged **Hypoglycemia** (especially with Glibenclamide in elderly/renal failure), weight gain (1–3 kg). **3. SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin)** * **Mechanism**: Selectively block the **Sodium-Glucose Cotransporter 2 (SGLT2)** in the S1/S2 segments of the proximal convoluted tubule, reducing renal glucose reabsorption threshold from 180 mg/dL to ~50 mg/dL and promoting daily glycosuria of 60–80 g (~240–320 kcal/day). * **Pivotal Non-Glycemic Benefits**: Landmark clinical trials (EMPA-REG, DAPA-HF) confirmed profound reductions in heart failure hospitalizations and progression of Chronic Kidney Disease (CKD), independent of diabetic status. * **Adverse Effects**: Mycotic genital infections (candidiasis), urinary tract infections, volume depletion/hypotension, and **Euglycemic Diabetic Ketoacidosis (euDKA)** during physiological stress or surgery. **4. GLP-1 Receptor Agonists (Semaglutide, Liraglutide) & DPP-4 Inhibitors (Sitagliptin)** * **Incretin Physiology**: GLP-1 is secreted by ileal L-cells in response to meals, stimulating glucose-dependent insulin release and suppressing glucagon. * **GLP-1 RA**: Subcutaneous or oral peptides that activate GLP-1 receptors; slow gastric emptying, suppress appetite (inducing 5–15% weight loss), and reduce major adverse cardiovascular events (MACE). Adverse effects: Nausea, vomiting; risk of medullary thyroid carcinoma and pancreatitis. * **DPP-4 Inhibitors**: Inhibit dipeptidyl peptidase-4 enzyme, prolonging endogenous GLP-1 half-life. Weight-neutral, well-tolerated, no hypoglycemia. **5. 📖 Standard Textbook Reference** * *KD Tripathi's Essentials of Medical Pharmacology*, 8th Ed., Ch. 19: Insulin and Oral Hypoglycemic Drugs, pp. 285–305. * *ADA Standards of Care in Diabetes—2024*, Ch. 9: Pharmacologic Approaches to Glycemic Treatment, pp. S158–S178.